Cover and contents : “Proceedings of the 11th CEReS Symposium on Enviromental Remote Sensing” February 23, 2009

2009年2月23日（月） 於 千葉大学けやき会

Blockade of either TLR2 or TLR4 reduces TNF-α and CXCL1 levels after polymicrobial sepsis.

<p>Mice were pre-treated with individual or combined anti-TLR2 or anti-TLR4 antibodies (45 minutes before the CLP procedure). Single treatment resulted in lower levels of TNF-α and CXCL1 (A and B, respectively) in the peritoneal cavity (PL: peritoneum lavage) and in serum (C and D, respectively) 6 hours after sepsis compared to the negative control isotype IgG antibody treatment (black bar). The combined treatment with both anti-TLR2 and anti-TLR4 presented similar response compared to negative isotype IgG treated-group. * p<0.05 between the CLP and Sham groups. # p<0.05 between the antibody treatment groups and negative control isotype IgG treated-group. Antibody dose (1 mg/animal). Used 6 animals/group, except isotype IgG antibody treated group (n = 10).</p

Combined effects of anti-TLR2, anti-TLR4 and antibiotics in polymicrobial sepsis.

<p>Mice were therapeutically treated with anti-TLR2, anti-TLR4 and antibiotics (metronidazole and ceftriaxone) separately or concomitantly 3 hours after the CLP procedure. The negative control isotype IgG antibody treatment was used as a control. n = 9–10 in each experimental group. * p<0.001 between use of the antibodies plus antibiotics and isotype IgG control and p<0.05 between individual use of antibodies or antibiotics. # p<0.05 between individual antibodies or antibiotics use and isotype IgG control. There was no difference in survival rates between mice given antibodies and antibiotics and the sham group (n = 10 animals/group). Antibody doses (1 mg/animal).</p

Blockade of either TLR2 or TLR4 reduces lung inflammation after polymicrobial sepsis.

<p>Mice were pre-treated with individual or combined anti-TLR2 or anti-TLR4 antibodies (45 minutes before the CLP procedure). Single treatment resulted in lower levels of TNF-α (A), IL-1β (B), CXCL1 (C) and myeloperoxidase in the lung 6 hours after sepsis compared to the negative control isotype IgG antibody treatment (black bar). The combined treatment with both anti-TLR2 and anti-TLR4 showed moderate improvement when compared to the control treatment-group. * p<0.05 between the CLP and Sham groups. # p<0.05 between the antibody treatment groups and negative control isotype IgG treated-group. Antibody dose (1 mg/animal). Used 6 animals/group, except isotype IgG antibody treated group (n = 10).</p

Blockade of either TLR2 or TLR4 improves inflammatory and infection indices in polymicrobial sepsis.

<p>Analysis of parameters of mice pre-treated (45 minutes before the CLP procedure) with individual anti-TLR2 or anti-TLR4 antibodies showed an increased neutrophil migration to the peritoneal cavity (A) and a decreased number of bacteria in peritoneum (B) and serum (C) 6 hours after sepsis compared to negative isotype IgG antibody treatment (black bar). The combined treatment with both anti-TLR2 and anti-TLR4 showed a similar inflammatory response compared to the negative control isotype IgG treated-group (CLP). * p<0.05 between the CLP and Sham groups. # p<0.05 between individual antibody treatments and negative control isotype IgG treated-group. Antibody dose (1 mg/animal). Horizontal bars in Fig 2A/2B represent median value. Used 6 animals/group, except isotype IgG antibody treated group (n = 10). Missing points in Figs reflect number of bacteria below detection limit.</p

Blockade of either TLR2 or TLR4 improves survival during polymicrobial sepsis.

<p>The survival rate was analyzed following CLP procedure comparing the effect of the treatment with isolated or combined anti-TLR2 and anti-TLR4 antibodies. The treatments were performed 45 minutes before (A) or 3 hours after (B) the CLP procedure. The combined treatment with both anti-TLR2 and anti-TLR4 showed a similar survival curve compared to the negative control isotype IgG treated-group (CLP) * P<0.001 between Individual antibody treatments and negative control (IgG). # p<0.05 between individual antibody treatments and negative control (IgG) Antibody dose (1 mg/animal). (n = 10/group).</p

Additional file 7: of A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease

Stimulation of IL-6 production by individual RASF samples and their response to NI-0101 treatment. These results suggest that individual RASF can cause variable levels of TLR4-dependent cytokine production by monocytes from patients with RA. (DOCX 1399 kb

Additional file 2: of A specific anti-citrullinated protein antibody profile identifies a group of rheumatoid arthritis patients with a toll-like receptor 4-mediated disease

Methodological approach used to identify NI-0101 responder samples and biomarkers. RA patient stratification methodology. (DOCX 27 kb